AtriCure gets some Wall Street love as Synergy wins a wary nod from the FDA's advisory panel

October 27, 2011 by MassDevice staff

AtriCure's Synergy surgical ablation system won an FDA panel recommendation for clearance, but advisors are split on the safety of the device.

AtriCure

AtriCure Inc. (NSDQ:ATRC) shares spiked almost 18 percent on news that the FDA's circulatory system devices panel voted in favor of the Synergy system.

Shares jumped to $11.76 this morning, recovering from a sudden drop in share price this week as documents leading up to the panel meeting revealed that advisors had concerns about Synergy's safety.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp